neoantigen-based therapeutic cancer vaccine GRT-R904

A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.